Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models

Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent

(2015) Neus Lozano et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma

(2014) Seyedeh Hoda Alavizadeh et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status

(2013) Roy van der Meel et al.   ADVANCED DRUG DELIVERY REVIEWS

A New Reagent for Stable Thiol-Specific Conjugation

(2013) George Badescu et al.   BIOCONJUGATE CHEMISTRY

Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma

(2013) Ommoleila Molavi et al.   BIOMATERIALS

Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas

(2013) Mohamadreza Amin et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo

(2012) Hiroshi Maeda et al.   ADVANCED DRUG DELIVERY REVIEWS

Doxil® — The first FDA-approved nano-drug: Lessons learned

(2012) Yechezkel (Chezy) Barenholz   JOURNAL OF CONTROLLED RELEASE

Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer

(2012) Jennifer I. Hare et al.   JOURNAL OF DRUG TARGETING

The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes

(2011) Jie Gao et al.   BIOMATERIALS

Hyperthermia-triggered intracellular delivery of anticancer agent to HER2+ cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2+ affisomes)

(2011) Brandon Smith et al.   JOURNAL OF CONTROLLED RELEASE

Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress

(2011) Twan Lammers et al.   JOURNAL OF CONTROLLED RELEASE

Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles

(2011) Seyed Amir Jalali et al.   Nanomedicine-Nanotechnology Biology and Medicine

Tumor delivery of macromolecular drugs based on the EPR effect

(2010) Vladimir Torchilin   ADVANCED DRUG DELIVERY REVIEWS

Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects

(2010) Kazuo Maruyama   ADVANCED DRUG DELIVERY REVIEWS

Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications

(2010) J. Löfblom et al.   FEBS LETTERS

Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro

(2010) Michaela L. Krieger et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing

(2009) Jie Gao et al.   BIOMATERIALS

Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models

(2009) Alberto Gabizon et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

HER-2-Targeted Nanoparticle-Affibody Bioconjugates for Cancer Therapy

(2008) Frank Alexis et al.   ChemMedChem

HER2-Specific Affibody-Conjugated Thermosensitive Liposomes (Affisomes) for Improved Delivery of Anticancer Agents

(2008) Anu Puri et al.   JOURNAL OF LIPOSOME RESEARCH

Preclinical Manufacture of an Anti-HER2 scFv-PEG-DSPE, Liposome-Inserting Conjugate. 1. Gram-Scale Production and Purification

(2005) David F. Nellis et al.   BIOTECHNOLOGY PROGRESS